KR20230145111A - 히드록시헤테로시클로알칸-카르바모일 유도체 - Google Patents

히드록시헤테로시클로알칸-카르바모일 유도체 Download PDF

Info

Publication number
KR20230145111A
KR20230145111A KR1020237030395A KR20237030395A KR20230145111A KR 20230145111 A KR20230145111 A KR 20230145111A KR 1020237030395 A KR1020237030395 A KR 1020237030395A KR 20237030395 A KR20237030395 A KR 20237030395A KR 20230145111 A KR20230145111 A KR 20230145111A
Authority
KR
South Korea
Prior art keywords
pyran
hydroxy
hydroxymethyl
carboxamide
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237030395A
Other languages
English (en)
Korean (ko)
Inventor
마르틴 볼리
욘 가트필트
코리나 그리소스토미
루보스 레멘
크리슈토프 자거
코르넬리아 춤브룬
Original Assignee
이도르시아 파마슈티컬스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이도르시아 파마슈티컬스 리미티드 filed Critical 이도르시아 파마슈티컬스 리미티드
Publication of KR20230145111A publication Critical patent/KR20230145111A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
KR1020237030395A 2021-02-09 2022-02-08 히드록시헤테로시클로알칸-카르바모일 유도체 Pending KR20230145111A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2021053084 2021-02-09
EPPCT/EP2021/053084 2021-02-09
PCT/EP2022/052948 WO2022171594A1 (en) 2021-02-09 2022-02-08 Hydroxyheterocycloalkane-carbamoyl derivatives

Publications (1)

Publication Number Publication Date
KR20230145111A true KR20230145111A (ko) 2023-10-17

Family

ID=80445748

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237030395A Pending KR20230145111A (ko) 2021-02-09 2022-02-08 히드록시헤테로시클로알칸-카르바모일 유도체

Country Status (13)

Country Link
US (1) US12304902B2 (cg-RX-API-DMAC7.html)
EP (1) EP4291556B1 (cg-RX-API-DMAC7.html)
JP (1) JP7844491B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230145111A (cg-RX-API-DMAC7.html)
CN (1) CN116806219A (cg-RX-API-DMAC7.html)
AU (1) AU2022221092A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207214A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002322A1 (cg-RX-API-DMAC7.html)
ES (1) ES3032987T3 (cg-RX-API-DMAC7.html)
IL (1) IL304923A (cg-RX-API-DMAC7.html)
TW (1) TW202246248A (cg-RX-API-DMAC7.html)
WO (1) WO2022171594A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202308643B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102863667B1 (ko) 2019-08-09 2025-09-23 이도르시아 파마슈티컬스 리미티드 (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
US12291520B2 (en) 2020-11-02 2025-05-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
IN2015DN02573A (cg-RX-API-DMAC7.html) 2012-10-31 2015-09-11 Galecto Biotech Ab
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
CA2970062C (en) 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
ES2734713T3 (es) 2015-07-06 2019-12-11 Gilead Sciences Inc Moduladores Cot y métodos de utilización de los mismos
CN109563119A (zh) 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CA3062649A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
KR102626669B1 (ko) 2017-05-12 2024-01-17 갈랙틴 사이언시즈, 엘엘씨 질환의 예방 및 치료를 위한 화합물 및 이의 용도
US11267811B2 (en) 2017-09-27 2022-03-08 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2019075045A1 (en) 2017-10-11 2019-04-18 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
JP2021501180A (ja) 2017-10-31 2021-01-14 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーGalectin Sciences, LLC 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用
CN113366007A (zh) 2018-10-15 2021-09-07 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂
CN113286632A (zh) 2018-10-15 2021-08-20 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂前药
US11447517B2 (en) 2018-11-21 2022-09-20 Galecto Biotech Ab Galactoside inhibitor of galectins
US12269819B2 (en) 2019-04-10 2025-04-08 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
JP7674276B2 (ja) 2019-07-03 2025-05-09 ガレクト バイオテック エービー ガレクチンの新規なガラクトシド阻害剤
CA3143078A1 (en) 2019-07-05 2021-01-14 Galecto Biotech Ab Novel galactoside inhibitor of galectins
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
KR102863667B1 (ko) 2019-08-09 2025-09-23 이도르시아 파마슈티컬스 리미티드 (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
US12291520B2 (en) 2020-11-02 2025-05-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives
WO2022184755A1 (en) 2021-03-03 2022-09-09 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Also Published As

Publication number Publication date
CN116806219A (zh) 2023-09-26
EP4291556C0 (en) 2025-04-23
EP4291556B1 (en) 2025-04-23
WO2022171594A1 (en) 2022-08-18
CL2023002322A1 (es) 2024-03-08
JP7844491B2 (ja) 2026-04-13
CA3207214A1 (en) 2022-08-18
IL304923A (en) 2023-10-01
ZA202308643B (en) 2026-03-25
ES3032987T3 (en) 2025-07-29
AU2022221092A1 (en) 2023-09-21
US20240124427A1 (en) 2024-04-18
TW202246248A (zh) 2022-12-01
JP2024506182A (ja) 2024-02-09
US12304902B2 (en) 2025-05-20
EP4291556A1 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
JP7604457B2 (ja) 2-ヒドロキシシクロアルカン-1-カルバモイル誘導体
EP4291556B1 (en) Hydroxyheterocycloalkane-carbamoyl derivatives
TWI910255B (zh) 2-羥環烷-1-胺甲醯基衍生物
JP7612663B2 (ja) (2-アセタミジル)チオ-ベータ-d-ガラクトピラノシド誘導体
JP7612662B2 (ja) (ヘテロ)アリール-メチル-チオ-ベータ-d-ガラクトピラノシド誘導体
KR20230083301A (ko) 알파-d-갈락토피라노사이드의 스피로 유도체
HK40101885A (en) Hydroxyheterocycloalkane-carbamoyl derivatives
HK40101885B (en) Hydroxyheterocycloalkane-carbamoyl derivatives
CN116745282A (zh) 抑制2-羟环烷-1-氨甲酰基衍生物的半乳糖凝集素-3
EA048927B1 (ru) Гидроксигетероциклоалканкарбамоильные производные
EA050798B1 (ru) 2-гидроксициклоалкан-1-карбамоильные производные, ингибирующие галектин-3
EA048291B1 (ru) 2-гидроксициклоалкан-1-карбамоильные производные
HK40071801A (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
HK40071801B (en) 2-hydroxycycloalkane-1-carbamoyl derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230906

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250203

Comment text: Request for Examination of Application